Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

SAMDC inhibitors from Ciba-Geigy

Sep. 20, 1996

Nitrogen mustard prodrugs from CRC Technology

Sep. 20, 1996

Daiichi's anticancer drugs in development

Sep. 13, 1996

Chugai's anticancer R&D pipeline

Sep. 13, 1996

Expanded approval sought for Photofrin

Sep. 13, 1996

Cytoprotective agent receives broad approval in Australia

Sep. 13, 1996

DNA repair gene isolated

Sep. 13, 1996

Site-specific catalytic cleavage of RNA achieved with ribozyme analogue

Sep. 13, 1996

Dolastatin 10 mimic dolaphenine androstane

Sep. 13, 1996

Antitumor agents from Samjin

Sep. 13, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.